According to , recently published report ‘Cystic Fibrosis – Pipeline Review, H2 2016’; Cystic Fibrosis pipeline therapeutics constitutes close to 137 molecules. Out of which approximately 121 molecules are developed by Companies and remaining by the Universities/Institutes.
Request sample at https://marketreportscenter.com/request-sample/438511
Furthermore, research says; Cystic Fibrosis Cystic fibrosis (CF) is an inherited disease of the mucus and sweat glands. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. The predisposing factors include family history and race (it is most common in white people of Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.
Check Discount at https://marketreportscenter.com/request-discount/438511
The report ‘Cystic Fibrosis – Pipeline Review, H2 2016’ outlays comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 20, 22, 52 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 6, 6 and 1 molecules, respectively.
Know more details of report, Table of content, list of figures or purchase report at https://marketreportscenter.com/reports/438511/cystic-fibrosis-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center